After GLP-1: Can the Industry Keep Up with the Peptide Pipeline?
Understandably, much of the last few years – and the rise of peptides – has been completely dominated by one or two products, namely the now ubiquitous GLP-1 drugs f...
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative